TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33436973

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) use
Number of subjects: 891395

Group type: COMPARATOR
Intervention: Control (non-ICS users)
Number of subjects: 891395
Study: 35433550

Group type: EXPERIMENTAL
Intervention: Transitional support program
Number of subjects: 80
Study: 34259400

Group type: EXPERIMENTAL
Intervention: Combination group (tapping at acupoints along meridian + thunder-fire moxibustion)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Acupoint-tapping group (tapping along the large intestine meridian)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Moxibustion group (thunder-fire moxibustion at affected side)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Routine group (routine treatment and nursing)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 140
Study: 35059825

Group type: EXPERIMENTAL
Intervention: Pronation-Extension (PE) position
Number of subjects: 50

Group type: COMPARATOR
Intervention: Neutral position
Number of subjects: 50
Study: 33469679

Group type: EXPERIMENTAL
Intervention: OVV-Beclin1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of OVV-Beclin1 and R-CHOP
Number of subjects: 0
Study: 33705273

Group type: EXPERIMENTAL
Intervention: 6 h group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 12 h group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 18 h group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 24 h group
Number of subjects: 120
Study: 34109609

Group type: EXPERIMENTAL
Intervention: 5% 5-Fluorouracil (5-FU) cream
Number of subjects: 0
Study: 33858561

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) combined with chemotherapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Traditional chemotherapy
Number of subjects: 35
Study: 32586362

Group type: EXPERIMENTAL
Intervention: Secondary-school-based intervention to reduce suicidal ideation among adolescents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community storage facility intervention to reduce access to pesticides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training for community health workers in recognition, management, and appropriate referral of people identified with high suicidal risk
Number of subjects: 0
Study: 36177741

Group type: EXPERIMENTAL
Intervention: metronidazole gel (0.75%)
Number of subjects: 130

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 130
Study: 33230561

Group type: EXPERIMENTAL
Intervention: IV iron sucrose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 0
Study: 32915158

Group type: EXPERIMENTAL
Intervention: Web-based individual physical activity challenge
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Web-based friend physical activity challenge
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Web-based team physical activity challenge
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Web-based intervention incorporating self-monitoring and physical activity challenges
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: External and identified regulations
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intrinsic and introjected regulations
Number of subjects: 76
Study: 34218516

Group type: EXPERIMENTAL
Intervention: Guided Biofilm Therapy (GBT) using erythritol powder (AIRFLOW®)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 50
Study: 33706750

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 10% high cleaning silica, 0.5% sodium phytate and 0.5% sodium pyrophosphate
Number of subjects: 86
Study: 32767983

Group type: EXPERIMENTAL
Intervention: Data Quality Assessments (DQA) conducted in health facilities from 2016 to 2018
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Data Quality Assessments (DQA) conducted in health facilities
Number of subjects: 444
Study: 35197363

Group type: COMPARATOR
Intervention: Tofacitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JAK inhibitors
Number of subjects: 0
Study: 32918512

Group type: EXPERIMENTAL
Intervention: 30-sec intervention including physician's very brief advice, a leaflet with graphic warnings, and a card with contact information of available cessation services
Number of subjects: 13671
Study: 32994251

Group type: EXPERIMENTAL
Intervention: 0.145% fluoride gel applied using custom trays after brushing every night while sleeping
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral hygiene instructions as usual
Number of subjects: 80
Study: 35803884

Group type: EXPERIMENTAL
Intervention: CFRD
Number of subjects: 117

Group type: COMPARATOR
Intervention: No CFRD
Number of subjects: 117
Study: 33902562

Group type: EXPERIMENTAL
Intervention: pNIV (portable non-invasive ventilation) with inspiratory/expiratory positive airway pressure of 18/8 cmH2O
Number of subjects: 61

Group type: COMPARATOR
Intervention: No pNIV (control group)
Number of subjects: 61
Study: 35156692

Group type: EXPERIMENTAL
Intervention: PBMS‐IMRT
Number of subjects: 40

Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 40
Study: 33650454

Group type: EXPERIMENTAL
Intervention: GENIE protocol (n = 382)
Number of subjects: 1404

Group type: COMPARATOR
Intervention: FORMULA protocol (n = 289)
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: GENIE overall (n = 1404)
Number of subjects: 1404

Group type: COMPARATOR
Intervention: Euglycemic no-insulin cohort (ENo-I, n = 111)
Number of subjects: 1404
Study: 35330828

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg in 10 min) followed by a constant infusion rate (0.5 μg kg−1 h−1) (D2 group)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Dexmedetomidine at a constant infusion rate (0.5 μg kg−1 h−1) (D1 group)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Propofol- and remifentanil-based total intravenous anesthesia (T group)
Number of subjects: 165
Study: 32860034

Group type: EXPERIMENTAL
Intervention: Colchicine initiated < Day 3
Number of subjects: 4661

Group type: EXPERIMENTAL
Intervention: Colchicine initiated between Days 4 and 7
Number of subjects: 4661

Group type: EXPERIMENTAL
Intervention: Colchicine initiated > Day 8
Number of subjects: 4661

Group type: EXPERIMENTAL
Intervention: Colchicine (early initiation)
Number of subjects: 4661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4661
Study: 36416665

Group type: EXPERIMENTAL
Intervention: Automated Oxygen Administration (AOA)
Number of subjects: 18
Study: 33331859

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg and 2.0 mg, administered monthly or on an as-needed basis over 24 months
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Ranibizumab (as-needed arm)
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 586
Study: 33544277

Group type: EXPERIMENTAL
Intervention: RUSH program (12-week intervention)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 55
Study: 33066098

Group type: EXPERIMENTAL
Intervention: Occupational physicians’ perspectives on employee participation in health promotion measures for musculoskeletal disorders (MSDs)
Number of subjects: 8
Study: 35777732

Group type: EXPERIMENTAL
Intervention: Positive incentive ($0.10/test)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Loss aversion ($100 for > 95% adherence)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control ($25 upon enrollment)
Number of subjects: 130
Study: 32237012

Group type: EXPERIMENTAL
Intervention: High-dose spironolactone (100 mg daily)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Low-dose spironolactone (25 mg daily)
Number of subjects: 149
Study: 37083373

Group type: EXPERIMENTAL
Intervention: sabatolimab + azacitidine
Number of subjects: 0
Study: 33497396

Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking (UCM)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Delayed Cord Clamping (DCC)
Number of subjects: 260
Study: 32531809

Group type: EXPERIMENTAL
Intervention: Colour illusion (blue tongue)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Baseline condition (normal size and colour tongue)
Number of subjects: 9
Study: 35637354

Group type: EXPERIMENTAL
Intervention: Neck stretching and movement exercises three times daily for four weeks post-surgery
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional follow-up without exercises
Number of subjects: 89
Study: 34064102

Group type: EXPERIMENTAL
Intervention: Creative Roots® (INT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 46
Study: 33029792

Group type: EXPERIMENTAL
Intervention: Tranexamic acid for PPH
Number of subjects: 18942
Study: 33952629

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 0
Study: 32699404

Group type: EXPERIMENTAL
Intervention: Leukocyte telomere length (LTL)
Number of subjects: 81000
Study: 34468959

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33279389

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose dabigatran (150 mg bid), rivaroxaban, high-dose edoxaban (60 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment with aspirin and P2Y12 receptor antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DOACs (Direct Oral Anticoagulants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori treatment
Number of subjects: 0
Study: 35137572

Group type: EXPERIMENTAL
Intervention: Lithium prolonged release (Li-PR)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Lithium immediate release (Li-IR)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Treatment satisfaction questionnaire
Number of subjects: 73
Study: 34308096

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 636

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 636
Study: 35112931

Group type: EXPERIMENTAL
Intervention: BH4 (≈10 mg/kg, post)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combined data from both approaches
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: BH4 supplementation
Number of subjects: 22
Study: 34746173

Group type: EXPERIMENTAL
Intervention: Web-based support program (SUPR)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: SUPR
Number of subjects: 138
Study: 35775183

Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hybrid fixation
Number of subjects: 19
Study: 34065588

Group type: EXPERIMENTAL
Intervention: Viewing images of nature
Number of subjects: 30

Group type: COMPARATOR
Intervention: Viewing images of built environments
Number of subjects: 30
Study: 32050789

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subcostal transversus abdominis plane (TAP) block with 30 mL local anesthetic (20 mL bupivacaine 0.125% plus 10 mL lidocaine 1%)
Number of subjects: 79

Group type: COMPARATOR
Intervention: IV analgesic management with paracetamol 1 g
Number of subjects: 79
Study: 34724584

Group type: EXPERIMENTAL
Intervention: THUNDERBEAT
Number of subjects: 60

Group type: COMPARATOR
Intervention: LigaSure
Number of subjects: 60
Study: 33207014

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU/d for 9 months)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 250
Study: 35190895

Group type: EXPERIMENTAL
Intervention: Tailored, Early Comprehensive Rehabilitation Program (t-ECRP)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 215
Study: 34903242

Group type: EXPERIMENTAL
Intervention: Artificial Neural Networks (ANNs)
Number of subjects: 3699

Group type: EXPERIMENTAL
Intervention: Multiple Linear Regression (MLR)
Number of subjects: 3699

Group type: EXPERIMENTAL
Intervention: Classification and Regression Tree (CART)
Number of subjects: 3699
Study: 34154951

Group type: EXPERIMENTAL
Intervention: Patient education intervention (two additional 1-hour sessions focused on the benign nature of LBP)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sham patient education (active listening only)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Feeling reassured (mediator)
Number of subjects: 202
Study: 33579199

Group type: EXPERIMENTAL
Intervention: Dexamethasone group (8 mg dexamethasone with 0.375% ropivacaine)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (ropivacaine only)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Dexamethasone group
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 32424409

Group type: EXPERIMENTAL
Intervention: Patient feedback intervention
Number of subjects: 43
Study: 35976631

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33972313

Group type: EXPERIMENTAL
Intervention: Early screening for undiagnosed diabetes and early hyperglycemia in pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current management regimen for GDM diagnosed at 24-28 weeks' gestation
Number of subjects: 0
Study: 33998024

Group type: EXPERIMENTAL
Intervention: Supportive periodontal therapy visits (SPT) with regularity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive periodontal therapy visits (SPT) with irregularity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive periodontal therapy visits (SPT)
Number of subjects: 0
Study: 33069413

Group type: EXPERIMENTAL
Intervention: Colostrum (COL)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1:1 colostrum:whole milk mixture (MX)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Whole milk (WM)
Number of subjects: 27
Study: 36017704

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/d
Number of subjects: 543

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 543
Study: 33411640

Group type: EXPERIMENTAL
Intervention: 1-h passive heating (40°C water) 30 min before an OGTT (HOT-OGTT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1-h passive heating (40°C water) 30 min after commencing an OGTT (OGTT-HOT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3-h OGTT (control)
Number of subjects: 12
Study: 35040869

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (vitE), dosage not specified, duration 3 years (baseline to year 3)
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (vitE) in never smokers
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (vitE) in current smokers
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (vitE) in former smokers
Number of subjects: 1144
Study: 33333334

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Twice-daily regimen of direct oral anticoagulants
Number of subjects: 41
Study: 33712967

Group type: EXPERIMENTAL
Intervention: Swab protocol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Brush protocol
Number of subjects: 25
Study: 34462881

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Spreading Depolarization (SD) monitoring
Number of subjects: 28

Group type: COMPARATOR
Intervention: Angiographic vasospasm
Number of subjects: 28

Group type: COMPARATOR
Intervention: Peripheral Cerebral Circulation Time (CCT)
Number of subjects: 28
Study: 32246398

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) images
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Panoramic Radiography (PR) images
Number of subjects: 250
Study: 33461323

Group type: EXPERIMENTAL
Intervention: Corticosteroid (40 mg methylprednisolone)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dextrose (20% dextrose)
Number of subjects: 44
Study: 34088588

Group type: EXPERIMENTAL
Intervention: Real (anodal) tDCS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study: 33057367

Group type: EXPERIMENTAL
Intervention: Higher systemic iron (lower sTFR and sTFR-ferritin index) and lower hsCRP levels in carriers of HFE variants
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Higher sTFR or iron stores, the HFE 187C>G variant, and lower baseline hsCRP
Number of subjects: 151
Study: 36112487

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) based counseling sessions via telephone (up to three sessions)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Information brochure on responsible Internet use
Number of subjects: 497
Study: 33852200

Group type: EXPERIMENTAL
Intervention: PRM 6 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose PRM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher-dose PRM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33231635

Group type: EXPERIMENTAL
Intervention: ECPR
Number of subjects: 916
Study: 35758433

Group type: EXPERIMENTAL
Intervention: Parenchyma-sparing resections (PSR)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Central pancreatectomies
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: No lymph nodes resected
Number of subjects: 810

Group type: COMPARATOR
Intervention: Oncologic resections
Number of subjects: 810
Study: 36309647

Group type: EXPERIMENTAL
Intervention: SVM model
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: LR model
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Combination of intermediate radiologist with LR radiomic model
Number of subjects: 201

Group type: COMPARATOR
Intervention: Empirical diagnosis
Number of subjects: 201
Study: 33813530

Group type: EXPERIMENTAL
Intervention: Symptom management PEDSS intervention
Number of subjects: 283

Group type: COMPARATOR
Intervention: Parent support and coping PEDSS intervention
Number of subjects: 283
Study: 35721014

Group type: EXPERIMENTAL
Intervention: Real continuous theta burst stimulation (cTBS) over the right cerebellar Crus I + 30-min speech-language therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham continuous theta burst stimulation (cTBS)
Number of subjects: 40
Study: 36339775

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 40 mg·kg‐1 + 10 mg·kg‐1·h‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil at an initial dose of 0.2 μg·kg‐1·min‐1
Number of subjects: 40
Study: 32590148

Group type: EXPERIMENTAL
Intervention: Walking in blue space
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Walking in urban space
Number of subjects: 59

Group type: COMPARATOR
Intervention: Resting at control site
Number of subjects: 59
Study: 34819273

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg (subcutaneous) at week 0, week 4, then every 8 weeks through week 44
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo (crossed over to guselkumab at week 24)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 32248626

Group type: EXPERIMENTAL
Intervention: Multifaceted counseling intervention with education and counseling by a physical therapist, use of a Fitbit and web application, and 4 follow-up calls from the physical therapist.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Multifaceted counseling intervention
Number of subjects: 118
Study: 36428216

Group type: EXPERIMENTAL
Intervention: IV melatonin at a daily dose of 60 mg, administered continuously for over 30 minutes starting on the day of diagnosis during a 5-day period.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 29
Study: 35641993

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX-A) injection in the lateral pterygoid muscle
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 38
Study: 35352277

Group type: EXPERIMENTAL
Intervention: Carbetocin 100 µg as a rapid intravenous bolus
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Carbetocin 100 µg over 10 min infusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (prophylactic phenylephrine infusion)
Number of subjects: 70
Study: 33226062

Group type: EXPERIMENTAL
Intervention: Iterative Mendelian Randomization and Pleiotropy (IMRP) approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 32053567

Group type: EXPERIMENTAL
Intervention: Group Integrated Neurocognitive Therapy (INT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 58
Study: 34184536

Group type: EXPERIMENTAL
Intervention: Site-specific labeling of IgG antibodies using a two-step protocol with microbial transglutaminase.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA-PAINT for labeling IgG antibodies.
Number of subjects: 0
Study: 32932174

Group type: EXPERIMENTAL
Intervention: 30 mg elemental zinc supplement
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 36171034

Group type: EXPERIMENTAL
Intervention: Peer reviewers received a data sheet with trial registration information during the intervention phase.
Number of subjects: 419

Group type: COMPARATOR
Intervention: Control phase with no changes to pre-existing peer review practices.
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Intervention phase compared to control phase.
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Intervention effect on primary outcomes.
Number of subjects: 419
Study: 33345813

Group type: EXPERIMENTAL
Intervention: Coronoidectomy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Coronoidotomy
Number of subjects: 32
Study: 32800005

Group type: EXPERIMENTAL
Intervention: Falls Management Exercise (FaME) programme
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (OEP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 35508201

Group type: EXPERIMENTAL
Intervention: Long Set Configuration (LSC: 4 sets of 10 repetitions with 2 min rest between sets)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Short Set Configuration (SSC: 8 sets of 5 repetitions with 51 s rest between sets)
Number of subjects: 24
Study: 32879929

Group type: EXPERIMENTAL
Intervention: Spinner group (spinning at 35 Ncm, n = 23)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stable group (stable at 35 Ncm, n = 27)
Number of subjects: 50